Updated on 15/03/2018
A large-scale study (n=1,306) compared the contraceptive efficacy, bleeding pattern, acceptability and safety of CERAZETTE to a progestogen-only pill containing 30 mcg of levonorgestrel.1
Compared to women in the levonorgestrel group, women in the CERAZETTE group tended to experience less bleeding over time, though the bleeding pattern showed more variability.1
Additionally, there was more amenorrhoea and more infrequent bleeding over time in the CERAZETTE group.1
There was a shift towards less bleeding and/or spotting days with CERAZETTE than with levonorgestrel.1
Frequent or prolonged bleeding1
Adapted from Collaborative Study Group on the Desogestrel-containing Progestogen-Only Pill, 19981
*Shifted reference period (days 29-118)
†Does not include breastfeeding participants
22.5% of participants discontinued treatment with CERAZETTE before cycle 1 due to irregular bleeding.
Discontinuation continued throughout the study.
Amenorrhoea and infrequent bleeding1
Adapted from Collaborative Study Group on the Desogestrel-containing Progestogen-Only Pill, 19981
*Shifted reference period (days 29-118)
†Does not include breastfeeding participants
The most commonly reported undesirable effects associated with CERAZETTE are bleeding changes,2 which are common to any method of progestogen-only contraception.3 Counselling women to expect changes in their bleeding pattern with progestogen-only contraception may increase their likely acceptance of the bleeding pattern.2
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
WOMN-1247519-0000 | Date of Preparation: March 2018